LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $61.17.

A number of equities research analysts have commented on LIVN shares. Wolfe Research cut LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Mizuho decreased their target price on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group dropped their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 25th. Finally, Stifel Nicolaus dropped their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th.

LivaNova Stock Down 4.1 %

Shares of LIVN stock opened at $35.95 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova has a one year low of $35.24 and a one year high of $64.48. The company’s fifty day moving average price is $43.47 and its 200-day moving average price is $48.08. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of 85.60 and a beta of 0.90.

Hedge Funds Weigh In On LivaNova

Several institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. increased its holdings in shares of LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after buying an additional 219 shares during the last quarter. Summit Investment Advisors Inc. grew its position in LivaNova by 1.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock worth $780,000 after acquiring an additional 289 shares in the last quarter. Central Pacific Bank Trust Division increased its stake in LivaNova by 7.0% during the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company’s stock worth $173,000 after acquiring an additional 290 shares during the last quarter. Xponance Inc. raised its position in LivaNova by 6.1% during the fourth quarter. Xponance Inc. now owns 7,762 shares of the company’s stock valued at $359,000 after purchasing an additional 445 shares during the period. Finally, Mariner LLC lifted its stake in shares of LivaNova by 8.4% in the 4th quarter. Mariner LLC now owns 5,741 shares of the company’s stock valued at $266,000 after purchasing an additional 446 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.